Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Top Page
Lisata Therapeutics
(NASDAQ:LSTA)
41Neutral
Positive Factors
Clinical Development
The completion of patient enrollment in the CENDIFOX study marks a significant clinical milestone, with study results expected to provide valuable data on treatment outcomes.
Licensing Agreement
A licensing agreement with Kuva Labs expands the potential use of certepetide beyond treatment into cancer diagnosis, creating significant added value.
Negative Factors
Financial Performance
Lisata announced 3Q24 financial results, posting EPS of ($0.59) compared to our estimate of ($0.77) and consensus of ($0.75).
Lisata Therapeutics (LSTA) vs. S&P 500 (SPY)
Market Cap
$20.60M
Dividend YieldN/A
Average Volume (3M)18.58K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue GrowthN/A
EPS Growth7.07%
CountryUS
Employees25
SectorHealthcare
Sector Strength77
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding8,620,162
10 Day Avg. Volume12,119
30 Day Avg. Volume18,579
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.60
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.00Price Target Upside527.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Lisata Therapeutics Business Overview & Revenue Model
Company DescriptionCaladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
How the Company Makes MoneyLisata Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company may earn money via partnerships with larger pharmaceutical companies, licensing agreements, and potential sales of its approved therapies. Additionally, Lisata could receive milestone payments and royalties based on the successful development and commercialization of its products. However, as a clinical-stage company, Lisata's revenue generation is typically dependent on the progression of its drug candidates through clinical trials and eventual regulatory approvals.
Lisata Therapeutics Financial Statement Overview
Summary
Lisata Therapeutics faces significant financial challenges with persistent losses and negative cash flows. Despite a strong equity position and no debt, the lack of revenue consistency and high operational costs are critical concerns. The company needs to address its cash burn rate and improve operational efficiencies.Income Statement
Lisata Therapeutics has faced significant challenges with revenue and profitability. The company reported a substantial net loss of $19,985,000 in the most recent year, despite a modest revenue of $1,000,000. Gross profit margin is quite high at 100% due to minimal cost of goods sold, but this is overshadowed by negative EBIT and EBITDA margins, indicating operational inefficiencies. The revenue growth rate is not applicable, given the absence of revenue in the prior year, which highlights volatility in revenue generation.30
Negative
Balance Sheet
The company's balance sheet shows moderate strength with a high equity ratio of 84.5%, and zero total debt suggesting financial prudence in leveraging. However, the return on equity is negative due to ongoing losses, which is a concern. Cash reserves have declined over the years, reflecting the company's cash burn rate amid its losses.45
Neutral
Cash Flow
The cash flow statement reveals a negative free cash flow of $19,356,000, indicating the company is not generating enough cash to cover its expenditures. The operating cash flow to net income ratio is positive, yet the absolute cash flow figures remain negative. The absence of capital expenditures suggests limited investment in growth initiatives.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.00M | 0.00 | 121.37M | 0.00 | 0.00 | Gross Profit |
| 1.00M | -189.00K | 63.77M | -55.00K | -63.00K | EBIT |
| -22.41M | -25.71M | -57.60M | -29.05M | -19.14M | EBITDA |
| -22.23M | -25.52M | -115.20M | -29.00M | -19.08M | Net Income Common Stockholders |
| -19.98M | -20.84M | -54.23M | -27.47M | -8.14M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 31.25M | 50.53M | 69.23M | 94.97M | 34.57M | Total Assets |
| 35.00M | 54.69M | 73.03M | 97.01M | 36.00M | Total Debt |
| 137.00K | 305.00K | 485.00K | 714.00K | 624.00K | Net Debt |
| -16.07M | -22.29M | -31.67M | -23.93M | -15.89M | Total Liabilities |
| 5.68M | 6.80M | 6.71M | 5.01M | 3.76M | Stockholders Equity |
| 29.57M | 48.15M | 66.58M | 92.25M | 32.50M |
| Cash Flow | Free Cash Flow | |||
| -19.36M | -20.03M | -21.45M | -22.30M | -8.84M | Operating Cash Flow |
| -19.36M | -20.03M | -21.17M | -22.25M | -8.82M | Investing Cash Flow |
| 13.23M | 10.10M | 28.91M | -54.90M | -7.28M | Financing Cash Flow |
| -206.00K | 385.00K | -224.00K | 85.28M | 18.58M |
Lisata Therapeutics Technical Analysis
Neutral
2.39
Price Trends
2.79
Negative
2.81
Negative
2.99
Negative
Market Momentum
-0.11
Negative
46.31
Neutral
47.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Neutral. The current price of 2.39 is above the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.79, and below the 200-day MA of 2.99, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 47.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LSTA.
Lisata Therapeutics Risk Analysis
Lisata Therapeutics disclosed 80 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lisata Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $533.88M | ― | 91.25% | ― | -17.75% | -19.17% | |
49 Neutral | $6.86B | 0.03 | -54.79% | 2.48% | 24.62% | -2.84% | |
48 Neutral | $448.11M | ― | -43.42% | ― | -5.97% | -25.87% | |
46 Neutral | $67.48M | ― | 91.63% | ― | 248.39% | 26.05% | |
42 Neutral | $240.78M | ― | -31.41% | ― | 389.82% | -22.66% | |
41 Neutral | $20.60M | ― | -51.43% | ― | ― | 7.07% | |
21 Underperform | $59.74M | ― | -3179.06% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
LSTA
Lisata Therapeutics
2.39
-0.65
-21.38%
EYPT
EyePoint Pharmaceuticals
6.52
-14.78
-69.39%
XOMA
Xoma
20.44
-4.74
-18.82%
AKBA
Akebia Therapeutics
2.26
0.37
19.58%
CLSD
Clearside Biomedical
0.89
-0.67
-42.95%
APLT
Applied Therapeutics
0.51
-5.45
-91.44%
Lisata Therapeutics Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -0.42% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in the development of certepetide, including regulatory achievements and a reduction in operating expenses. However, low revenue generation and ongoing net losses pose challenges. The uncertainty surrounding the release of key trial data further complicates the outlook.Highlights
Advancement of Certepetide Development Portfolio
Lisata has advanced its development portfolio centered around certepetide for treating advanced solid tumors. Encouraging preliminary results from the ASCEND and iLSTA trials were presented at the 2025 ASCO GI Symposium.
Operating Expense Reduction
Operating expenses for 2024 totaled $23.4 million, a decrease of $2.3 million or 8.9% from 2023.
Cash Reserves and Funding
As of December 31, 2024, Lisata had cash, cash equivalents, and marketable securities of approximately $31.2 million, expected to support operations into Q2 2026.
Regulatory Achievements
Certepetide received several orphan drug designations, a fast track designation, and a rare pediatric disease designation in multiple jurisdictions.
Lowlights
Revenue Remains Low
Revenue for the year ended December 31, 2024, was only $1 million, indicating minimal income generation from operations.
Net Loss
Net losses were $20 million for 2024, slightly improved from $20.8 million in 2023 but still indicating significant financial losses.
Uncertainty in Data Release
There is uncertainty regarding the release of Cohort B data from the ASCEND trial, which could impact timelines and investor confidence.
Company Guidance
During the Lisata Therapeutics' Full Year 2024 Financial Results and Business Update Conference Call, the company reported key financial metrics and provided guidance on upcoming milestones. For the fiscal year ending December 31, 2024, Lisata generated $1 million in revenue, primarily from an upfront license fee, and incurred operating expenses totaling $23.4 million, a decrease of $2.3 million from 2023. Research and development expenses dropped by $1.4 million to $11.3 million, largely due to reduced costs for the Phase 2b ASCEND trial, while general and administrative expenses decreased by $0.9 million to $12.1 million. The net loss for 2024 was $20 million, slightly improved from the $20.8 million loss in 2023. Cash reserves stood at $31.2 million, projected to sustain operations into Q2 2026. Key upcoming milestones in 2025 include data releases from various clinical trials involving certepetide in cancer and other therapeutic areas, with a focus on advancing clinical and preclinical programs.Lisata Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Lisata Therapeutics Reports 2024 Financial Results and Updates
Positive
Feb 27, 2025
On February 27, 2025, Lisata Therapeutics reported its financial results for the fiscal year ending December 31, 2024, and provided a business update. The company highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial for certepetide. Lisata is advancing its development portfolio with multiple milestones expected over the next year, supported by a cash runway extending into the second quarter of 2026. The company is conducting several clinical trials globally, focusing on the efficacy of certepetide in combination with standard-of-care treatments for various cancers, including pancreatic, cholangiocarcinoma, and glioblastoma.
Product-Related AnnouncementsBusiness Operations and Strategy
Lisata Therapeutics Reports Positive Phase 2 Trial Results
Positive
Jan 23, 2025
On January 22, 2025, Lisata Therapeutics announced preliminary positive results from Cohort A of the Phase 2 ASCEND trial for its investigational drug certepetide in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma. The data showed a median overall survival of 12.68 months for the certepetide group compared to 9.72 months for the placebo group, with four complete responses observed in the certepetide group. The findings are expected to support further development into Phase 3 trials, with data from Cohort B anticipated in the coming months, potentially enhancing the company’s standing in the oncology market.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.